|1.||Theppisai, Urusa: 1 article (09/2003)|
|2.||Suchartwatnachai, Charnchai: 1 article (09/2003)|
|3.||Manonai, Jittima: 1 article (09/2003)|
|4.||Jorgensen, Lars Nelleman: 1 article (09/2003)|
|5.||Jirapinyo, Mayuree: 1 article (09/2003)|
|6.||Liang, Wei-Hsing: 1 article (01/2002)|
|7.||Yuan, Chiou-Chung: 1 article (01/2002)|
|8.||Yang, Tzay-Shing: 1 article (01/2002)|
|9.||Chang, Sheng-Ping: 1 article (01/2002)|
|10.||Eliseeva, N A: 1 article (01/2001)|
12/01/2000 - "The bleeding pattern was generally highly satisfactory and similar to that with Kliogest, as were the results of endometrial biopsies after 12 cycles of treatment. "
06/01/2000 - "A greater proportion of women in the Kliogest and E2Val 2/DNG 3 groups experienced vaginal bleeding, whereas breast problems were more common with Climodien. "
06/01/2000 - "Climodien appeared to be superior to Kliogest in terms of vaginal bleeding pattern, whereas E2Val 2/DNG 3 was associated with a slightly higher incidence and greater intensity of vaginal bleeding. "
05/01/1996 - "The aim of this study was to compare a new estradiol-desogestrel (E2-DG) regimen with an E2-norethisterone acetate (NETA) combination (Trisekvens) regarding the treatment of menopausal complaints, bleeding pattern, histology of the endometrium and the occurrence of adverse experiences. "
|3.||Uterine Hemorrhage (Uterine Bleeding)
09/01/2003 - "The frequency and severity of treatment-related uterine bleeding decreased with the duration of Kliogest treatment. "
01/01/1991 - "The authors describe the results from 30 women with premenopausal uterine bleedings and accompanying neuro-autonomic climacteric symptoms, treated with the combined estrogestagenic preparation (Trisequens--Novo Nordisk A/S). "
01/01/1991 - "[The treatment and prevention of premenopausal uterine hemorrhages with Trisequens]."
01/01/2002 - "There was no report of serious adverse events, endometrial hyperplasia or cancer in the Kliogest treated patients. "
11/01/2000 - "1. To determine the prevalence of endometrial hyperplasia in postmenopausal women taking standard proprietary regimens of sequential oestrogen/progestogen; 2. to determine the effects of nine months treatment with an oral continuous combined regimen of 2 mg 17beta-oestradiol and 1 mg norethisterone acetate (Kliofem [Kliogest outside the UK]; Novo Nordisk, Denmark) on endometrial histology in postmenopausal women. "
|5.||dienogest drug combination estradiol Valerate
|6.||norethindrone acetate (Norlutate)